Definium Therapeutics (NASDAQ:DFTX) Given New $36.00 Price Target at Royal Bank Of Canada

Definium Therapeutics (NASDAQ:DFTX) had its price target lifted by Royal Bank Of Canada from $20.00 to $36.00 in a research report sent to investors on Friday, MarketBeat Ratings reports. They currently have an outperform rating on the stock.

DFTX has been the subject of a number of other reports. Needham & Company LLC reaffirmed a “buy” rating on shares of Definium Therapeutics in a research report on Monday, January 5th. Canaccord Genuity Group boosted their target price on Definium Therapeutics from $16.00 to $25.00 and gave the stock a “buy” rating in a research note on Friday, November 7th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Definium Therapeutics in a report on Wednesday, October 8th. Chardan Capital upgraded Definium Therapeutics to a “strong-buy” rating in a report on Wednesday, November 19th. Finally, Jones Trading initiated coverage on Definium Therapeutics in a research note on Tuesday, December 23rd. They issued a “buy” rating and a $61.00 price objective for the company. Three equities research analysts have rated the stock with a Strong Buy rating, eight have given a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Buy” and a consensus price target of $32.11.

Definium Therapeutics Trading Up 2.5%

NASDAQ DFTX opened at $17.40 on Friday. The company has a current ratio of 3.30, a quick ratio of 3.30 and a debt-to-equity ratio of 0.31. The business has a fifty day simple moving average of $13.16 and a 200 day simple moving average of $11.42. Definium Therapeutics has a 12 month low of $4.70 and a 12 month high of $18.12. The firm has a market capitalization of $1.71 billion, a P/E ratio of -8.53 and a beta of 2.57.

Definium Therapeutics (NASDAQ:DFTX) last posted its quarterly earnings data on Thursday, November 6th. The company reported ($0.78) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.52) by ($0.26). On average, analysts predict that Definium Therapeutics will post -1.35 EPS for the current fiscal year.

Insider Buying and Selling at Definium Therapeutics

In other Definium Therapeutics news, insider Daniel Karlin sold 5,600 shares of the firm’s stock in a transaction on Friday, December 26th. The stock was sold at an average price of $13.15, for a total value of $73,640.00. Following the completion of the sale, the insider directly owned 425,025 shares of the company’s stock, valued at $5,589,078.75. This trade represents a 1.30% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, CEO Robert Barrow sold 25,791 shares of the business’s stock in a transaction dated Friday, December 26th. The shares were sold at an average price of $13.15, for a total value of $339,151.65. Following the completion of the sale, the chief executive officer owned 778,477 shares in the company, valued at $10,236,972.55. This represents a 3.21% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders sold 42,667 shares of company stock valued at $561,071. Company insiders own 2.26% of the company’s stock.

Institutional Trading of Definium Therapeutics

Institutional investors have recently modified their holdings of the business. Russell Investments Group Ltd. grew its stake in Definium Therapeutics by 110.4% in the 2nd quarter. Russell Investments Group Ltd. now owns 3,817 shares of the company’s stock valued at $25,000 after buying an additional 2,003 shares in the last quarter. BIT Capital GmbH bought a new position in shares of Definium Therapeutics in the third quarter worth $26,000. CWM LLC grew its position in shares of Definium Therapeutics by 67.4% in the second quarter. CWM LLC now owns 4,459 shares of the company’s stock valued at $29,000 after purchasing an additional 1,796 shares in the last quarter. Fifth Third Bancorp raised its stake in shares of Definium Therapeutics by 5,593.2% during the 3rd quarter. Fifth Third Bancorp now owns 3,359 shares of the company’s stock valued at $40,000 after purchasing an additional 3,300 shares during the period. Finally, Sound Income Strategies LLC purchased a new stake in Definium Therapeutics during the 3rd quarter worth about $46,000. 27.91% of the stock is currently owned by hedge funds and other institutional investors.

Definium Therapeutics Company Profile

Definium Therapeutics, Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of core symptoms of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc and changed its name to Definium Therapeutics, Inc in January 2026.